# Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

> **NCT05642962** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Pancreatic Carcinoma
- Pancreatic Carcinoma
- Pancreatic Carcinoma Metastatic
- Pancreatic Carcinoma Non-resectable
- Pancreatic Cancer
- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Stage IV
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Pertzye

## Key facts

- **NCT ID:** NCT05642962
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-30
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642962, "Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05642962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*